Using PET imaging to improve radiation therapy for high-risk meningiomas
Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas.
This study is testing if using special PET scans to guide higher doses of radiation therapy can help men with high-risk meningiomas live longer without their cancer getting worse.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 53 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Aviano, Pordenone) |
| Trial ID | NCT06830356 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of somatostatin receptor PET imaging to guide the escalation of radiation therapy doses in patients with high-risk meningiomas. By utilizing PET imaging, the study aims to better define the radiation treatment volume compared to standard MRI methods. The goal is to determine if higher doses of radiation, tailored using PET imaging, can be safely administered and lead to improved progression-free survival rates. Participants will receive radiation treatment based on the findings from their PET scans.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 16 and older with grade III meningioma or recurrent grade II meningioma who have not previously undergone brain-level radiotherapy.
Not a fit: Patients with grade I meningiomas or those who have had radical resection of grade II meningiomas at first diagnosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved disease control and longer survival for patients with high-risk meningiomas.
How similar studies have performed: While the use of PET imaging in radiation therapy is gaining interest, this specific approach to dose escalation in meningiomas is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 16 years; * Ability to express appropriate informed consent to treatment; * Diagnosis of grade III meningioma (regardless of presence of residual) or diagnosis of recurrence of grade II meningioma (regardless of presence of residual) or first diagnosis of grade II meningioma with presence of residual; * In case of recurrence, confirmation can be either histological or radiological; * Not previous brain-level radiotherapy; * Performance status: ECOG=0-2. Exclusion Criteria: * Refusal to radiation treatment (i.e., absence of signed informed consent); * Other concomitant oncologic therapies * Current pregnancy; * Grade I meningiomas or Grade II meningiomas if operated on at first diagnosis with radical resection; * Inability to perform MRI with MoC or PET.
Where this trial is running
Aviano, Pordenone
- Centro di Riferimento Oncologico di Aviano (CRO) — Aviano, Pordenone, Italy (Recruiting)
Study contacts
- Principal investigator: Lorenzo Vinante — Centro di Riferimento Oncologico di Aviano (CRO)
- Study coordinator: Lorenzo Vinante
- Email: lorenzo.vinante@cro.it
- Phone: 0434 659855
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.